Barclays lowered the firm’s price target on Pacira to $50 from $57 and keeps an Overweight rating on the shares. The analyst says the Q3 Exparel revenue miss and subsequent guidance cut came in-line with the firm’s expectations. The firm says the stock needs Exparel momentum.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on PCRX:
- Pacira BioSciences to Participate in Fireside Chat at Two Healthcare Conferences in November
- Pacira price target lowered to $57 from $63 at H.C. Wainwright
- Pacira price target lowered to $58 from $67 at RBC Capital
- Pacira price target lowered to $45 from $52 at Needham
- Pacira BioSciences Reports Third Quarter 2023 Financial Results
